Telix Pharmaceuticals Limited
TLX
Xếp hạng trong cổ phiếu
#4425
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Giá cổ phiếu
$10.20
Vốn hóa thị trường
$3.47B
Thay đổi (1 ngày)
-1.41%
Thay đổi (1 năm)
-7.29%
Quốc gia
AU
Giao dịch Telix Pharmaceuticals Limited (TLX)
Danh mục
Healthcare
Doanh thu của Telix Pharmaceuticals Limited (TLX)
Doanh thu vào Jun 2026 TTM: $924.21M
Theo các báo cáo tài chính gần đây của Telix Pharmaceuticals Limited, doanh thu hiện tại của công ty (TTM) là $924.21M. Trong năm 2023, công ty đạt doanh thu $342.34M tăng so với doanh thu năm 2022, là $108.95M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Telix Pharmaceuticals Limited từ 2000 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $924.21M | 89.78% |
| 2024 | $487.00M | 42.26% |
| 2023 | $342.34M | 214.23% |
| 2022 | $108.95M | 1,873.24% |
| 2021 | $5.52M | 37.53% |
| 2020 | $4.01M | 64.21% |
| 2019 | $2.44M | 1,679.60% |
| 2018 | $137.38K | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $12.62B | 1,265.95% |
US
|
|
| $2.23B | 141.07% |
US
|
|
| $15.74B | 1,603.54% |
AU
|
|
| $6.02B | 551.51% |
NL
|
|
| - | - |
CH
|
